Peptide 'glow up' claims on TikTok: what the science says

What did @westendmedspa actually say?

The creator ran through a quick-hit list of five compounds they'd recommend for a "summer glow up." The list included Tesamorelin for "burning stubborn visceral fat," NAD+ for "a little bit of boost to energy and mental clarity," something called "reda" for fat loss described as "an absolute nuclear bomb," a vague "glow stack" covering skin, hair, nails, and anti-aging, and PT-141, introduced with the knowing wink "if you know you know." Five compounds, sixty seconds, zero dosing context, zero safety caveats. That's the whole pitch.

A few things jump out immediately. NAD+ is not a peptide. "Reda" is almost certainly Retatrutide, a GLP-1/GIP/glucagon triple agonist still in clinical trials. And PT-141, also known as bremelanotide, is an FDA-approved drug for hypoactive sexual desire disorder in women, not a cosmetic compound. Calling it a "glow up" tool is a creative reframe, to put it charitably.

Does the science back this up?

Some of it does, partially. Tesamorelin has the strongest evidence base here. It's FDA-approved specifically for HIV-associated lipodystrophy, and studies confirm it reduces visceral adipose tissue. The fat-loss claim isn't invented. But "stubborn visceral fat" in a general wellness context is a different population than the clinical trials studied.

NAD+ precursors like NMN and NR have shown some promise in early human trials, but calling NAD+ itself a peptide is flatly wrong. It's a coenzyme. Iyer et al. (2023, Aging Cell) found modest improvements in muscle function with NMN supplementation, but "energy and mental clarity" as a blanket benefit overstates the current evidence significantly.

Retatrutide, if that's what "reda" means, is not approved anywhere. Phase 2 data from Jastreboff et al. (2023, NEJM) showed up to 24% body weight reduction, which is genuinely remarkable, but it is an investigational drug. Calling it a bomb you'd casually recommend is irresponsible framing. The "glow stack" is never defined, which makes it impossible to evaluate. GHK-Cu has some legitimate skin-remodeling data (Pickart et al., 2015, Journal of Aging Science), but stacking unnamed compounds is not a verifiable claim.

What did they get wrong (or right)?

They got Tesamorelin's mechanism right. The visceral fat reduction data is real. Credit where it's due. But the framing of "stubborn visceral fat" for a general summer audience skips the part where this drug is studied in people with a specific medical condition, not healthy people who want to lean out before June.

Calling NAD+ a peptide is simply wrong. It's a basic categorization error that undermines the credibility of the whole list. NAD+ is a coenzyme involved in cellular energy metabolism, not a peptide chain.

"Reda" as a casual fat-loss recommendation is the most concerning item here. Retatrutide has no approved human use. Recommending investigational compounds to 621,000 viewers as a glow-up tool, with no clinical context, no mention of trial status, and no safety information, is exactly the kind of content that gets people into trouble with compounding pharmacies or gray-market suppliers.

PT-141 is FDA-approved, but not for skin or general wellness. It works on melanocortin receptors and is indicated for female sexual dysfunction. The "if you know you know" framing implies off-label use for libido, which is common in wellness circles, but presenting it as a cosmetic compound misleads viewers about what it actually does and how it's regulated.

What should you actually know?

Several of these compounds are either investigational, FDA-approved only for specific conditions, or not peptides at all. That matters because how a compound is regulated determines how it can legally be prescribed, compounded, and sold. Using an investigational drug like Retatrutide outside of a clinical trial means sourcing it from unregulated channels, which carries real risk.

Tesamorelin and PT-141 are legitimate pharmaceutical compounds, but they require a prescription and medical evaluation. NAD+ infusions and oral precursors are widely available, but the evidence for dramatic benefits in healthy adults is weaker than the wellness industry suggests. The "glow stack" is undefined, which should be a red flag in any clinical conversation.

If you're genuinely curious about any of these compounds, the conversation starts with a licensed provider who can review your labs, your health history, and whether the compound has a legitimate evidence base for your specific situation. A sixty-second TikTok list is not a treatment plan.